Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Launches COVID-19 Technology Access Pool

IGBA Supports C-TAP, Which Encourages Sharing IP And Data

Executive Summary

C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

You may also be interested in...



MPP And WHO Announce COVID Technology License Via C-TAP

The WHO and Medicines Patent Pool have announced “the first transparent, global, non-exclusive license for a COVID-19 technology” after striking a deal for a COVID-19 serological antibody technology with the Spanish National Research Council through the WHO’s COVID-19 Technology Access Pool.

MPP And IGBA Initiatives Bolster COVID-19 Access

The Medicines Patent Pool and the International Generic and Biosimilar medicines Association have announced separate initiatives with the continued intention to facilitate access to COVID-19 treatments and vaccines, as the global threat from the novel coronavirus pandemic continues.

Coronavirus Update: GSK Stresses Need For Broad Vaccines Amid Future Pandemic Risk

Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel